Share on StockTwits

DexCom (NASDAQ:DXCM) CEO Terrance H. Gregg unloaded 23,893 shares of DexCom stock on the open market in a transaction dated Thursday, August 21st. The stock was sold at an average price of $44.36, for a total value of $1,059,893.48. Following the completion of the transaction, the chief executive officer now directly owns 395,626 shares of the company’s stock, valued at approximately $17,549,969. The transaction was disclosed in a filing with the SEC, which is available at this link.

A number of analysts have recently weighed in on DXCM shares. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, August 8th. They now have a $46.00 price target on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Thursday, August 7th. They now have a $46.00 price target on the stock, up previously from $44.00. Finally, analysts at Canaccord Genuity raised their price target on shares of DexCom from $40.00 to $48.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the company. DexCom has a consensus rating of “Hold” and an average target price of $41.00.

DexCom (NASDAQ:DXCM) traded down 1.36% during mid-day trading on Thursday, hitting $43.54. The stock had a trading volume of 692,515 shares. DexCom has a 1-year low of $25.49 and a 1-year high of $49.83. The stock has a 50-day moving average of $39.65 and a 200-day moving average of $38.91. The company’s market cap is $3.286 billion.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.10) by $0.01. The company had revenue of $58.80 million for the quarter, compared to the consensus estimate of $52.45 million. During the same quarter last year, the company posted ($0.14) earnings per share. DexCom’s revenue was up 64.2% compared to the same quarter last year. Analysts expect that DexCom will post $-0.32 EPS for the current fiscal year.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.